Delcath Systems reports Q3 EPS ($1.14), consensus (52c)

Reports Q3 revenue $400,000, consensus $680,000. Research and development expenses for the quarter were $4.7M, compared to $4.1M in the prior year quarter.”The Company has been preparing for a January launch of HEPZATO KIT by building our commercial team and engaging with potential treating centers,” said Gerard Michel, CEO of Delcath. Michel added, “We have been encouraged by the reception that HEPZATO KIT has received from the medical oncologist community and are confident that by the end of 2024 at least 15 centers will be actively treating metastatic uveal melanoma patients with HEPZATO KIT.”